Bli medlem
Bli medlem

Du är här


ObsEva SA: ObsEva Presents Pharmacology Data Showing that OBE001, the First Orally Active Oxytocin Antagonist, Inhibits not only Uterine Contractions but also

ObsEva SA / ObsEva Presents Pharmacology Data Showing that OBE001, the First
Orally ActiveOxytocin Antagonist, Inhibits not only Uterine Contractions but
also Preterm Labor Related Inflammation Pathways. Processed and transmitted
by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the
content of this announcement.
Geneva,Switzerland, 01 September 2015 - ObsEva
, a Swiss biopharmaceutical company developing a novel generation of drugs
addressing serious conditions compromising pregnancy from conception to
birth, presented today the data of ex-vivo pharmacology studies with its lead
compound, OBE001, a novel orally active oxytocin receptor antagonist. The
studies comprised the assessment of contractions in uterine muscle
(myometrium) explants obtained from pregnant women and the effects on
oxytocin-induced inflammatory responses in human gestational tissues. OBE001
was compared to the marketed oxytocin receptor antagonist, Atosiban, which is
administered by intravenous infusion. The results of the pharmacology
studies have been presented today at the European Society for Translational
Medicine meeting in Vienna, Austria.

Oxytocin plays a key role in term and preterm labor - it is one of the
strongest agents to stimulate uterine contractions. Oxytocin is also known
for its pro-inflammatory role in human gestational tissues which further
contributes to labor. Tocolytics targeting the oxytocin system should ideally
inhibit contractions and inflammation in the context of preterm labor.

The contractility study compared the effects of equimolar concentrations of
OBE001 and Atosiban upon spontaneous and oxytocin-induced contractions of
human pregnant myometrium tissue ex vivo. Atosiban had no effect upon
spontaneous contractions but dose-dependently antagonized the effects of
oxytocin. In contrast, OBE001 inhibited both spontaneous and oxytocin-induced
contractions in a dose-dependent manner and led, unlike Atosiban, to complete
abolishment of contractility at high concentrations.

The potential of OBE001 to inhibit the oxytocin-driven activation of
inflammatory responses was evaluated in cultured myometrium and amnion
primary cells. In contrast to findings with Atosiban, presence of OBE001 and
oxytocin led to significant inhibition of oxytocin-induced inflammatory
pathways activation (NF-KB and p38 proteins) and translated into suppression
of inflammatory mediators known to be associated with labor (COX-2, IL-6,
IL-8 and CCL2). OBE001 alone had no significant effect on the activation of
NF-KB and p38 pathways and downstream pro-labor gene expression whereas
Atosiban alone activated inflammatory pathways.

"Our data suggests that OBE001 is a promising candidate tocolytic, as it
ensures effective inhibition of uterine contractility and suppresses the
oxytocin-driven pro-inflammatory effects in gestational tissues. Acting on
several pathways leading to labor, OBE001 appears to have a superior
tocolytic profile than Atosiban."
said Oliver Pohl, Senior Director Non-Clinical Development and Phase 1 of
ObsEva. Professor Phillip Bennett of ObsEva's Scientific Advisory Board
added"Prematurity is now recognised to be the biggest cause of the death of
babies throughout the world. It is also one of the major causes of long term
handicap. There is an urgent need for treatments which can prevent or delay
preterm birth safely. Our studies in the laboratory show that OBE001
potentially has significant advantages over the drugs currently in use which
is very encouraging as the drug enters Phase 2 studies in women who are in
preterm labor."

- ends -

About Preterm Labor

According to The Global Action Report on Preterm Birth "Born Too Soon" issued
by World Health Organization in 2012, 15 million babies are born too soon
(born before 37 weeks of gestation) every year. This represents more than 1
in 10 babies worldwide. Over 1 million children die each year due to
complications of preterm birth and many survivors face a lifetime of
disability. The rates of preterm births are rising in almost all countries
and are associated with an important financial burden to the society. The
annual healthcare costs associated with preterm births was estimated in 2005
at approximately 27 billion USD in the USA. Costs after the neonatal period
for lifetime medical&special services reach more than 500 thousand USD per
premature handicapped child. Preterm labor is characterized by premature
uterus contractions leading to birth before 37 weeks.

About OBE001

OBE001 is a new generation oxytocin antagonist. Oxytocin antagonists are
potent inhibitors of uterine contractions. OBE001 is a compound for oral
treatment of preterm labor and is being studied in a Phase 2 proof of concept
study for delaying preterm birth. For additional information, please visit and see the Press release dated 23 June 2015.

About ObsEva

ObsEva is a clinical stage biopharmaceutical company focusing on the
development of a novel generation of drugs addressing serious conditions
compromising pregnancy from conception to birth. Our lead programs target the
underserved problems of infertility and preterm labor affecting more and more
women worldwide. The ObsEva team's unique development expertise is supported
by top-tier investors in order to build a leading company in pregnancy

For more information, please

For further information, please contact ObsEva CEO Office:
Delphine Renaud
Tel: +41 22 552 1550

Press release (PDF)


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ObsEva SA via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.